Journal of Hepatology
Volume 54, Issue 1 , Pages 108-114, January 2011

Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting

  • Caroline Tournoux-Facon

      Affiliations

    • Unité d’Epidémiologie et Biostatistique, Inserm CIC P802, CHU Poitiers, Université de Poitiers, France
  • ,
  • Xavier Paoletti

      Affiliations

    • Service de Biostatistique, Institut Curie, Paris, France
    • INSERM U900, Paris, France
    • Corresponding Author InformationCorresponding author at: Service de Biostatistique, Institut Curie, Paris, France. Tel.: +33 1 56 24 56 47; fax: +33 1 53 10 40 20.
  • ,
  • Jean-Claude Barbare

      Affiliations

    • Délégation à la Recherche Clinique et à l’Innovation, CHU Amiens, France
  • ,
  • Olivier Bouché

      Affiliations

    • Service d’Hépatogastroentérologie, CHU Reims, France
  • ,
  • Philippe Rougier

      Affiliations

    • Hépato-gastro-entérologie, oncologie digestive, Hôpital Ambroise Paré, Boulogne, France
  • ,
  • Laetitia Dahan

      Affiliations

    • Service d’Hépatogastroentérologie et Oncologie Digestive, CHRU AP-HM La Timone, Université de la Méditerranée, Marseille, France
  • ,
  • Catherine Lombard-Bohas

      Affiliations

    • Service d’Hépatogastroentérologie, CHRU Lyon, France
  • ,
  • Roger Faroux

      Affiliations

    • Service d’Hépatogastroentérologie, CH La Roche sur Yon, France
  • ,
  • Jean Luc Raoul

      Affiliations

    • Centre Régional de Lutte Contre le Cancer Eugène Marquis, Rennes, European University in Brittany, France
  • ,
  • Laurent Bedenne

      Affiliations

    • FFCD, INSERM U-866, Dijon, France
  • ,
  • Franck Bonnetain

      Affiliations

    • Unité de biostatistiques et de méthodologie, FFCD, INSERM U-866, Dijon, France

Received 21 September 2009; received in revised form 2 June 2010; accepted 18 June 2010. published online 31 August 2010.

Background & Aims

Patients with hepatocellular carcinoma (HCC) in a palliative setting have a poor prognosis despite recent therapeutic progress. Several prognostic scores, such as the BCLC and the CLIP, have been shown to be useful in helping select treatment options ranging from transplantation to palliative care. However, the discriminatory ability of these scores is inadequate in palliative settings, which concern about 70% of HCC patients. In this paper, we propose and validate a new prognostic score for patients in the palliative setting.

Methods

The prognostic score was developed on a set of 416 patients from a negative randomized clinical trial conducted by the Fédération Francophone de Cancers Digestifs. It was then subsequently validated on a second set of 271 patients from another negative trial. Backward selection was used to identify independent baseline characteristics. Measures of discrimination and predictive values were computed to assess the quality of the developed score. Comparisons with the BCLC and the CLIP – with and without the WHO performance status (PS) score – were performed.

Results

Tumour morphology, portal vein obstruction, metastasis, ascites, jaundice, alpha-foetoprotein, and serum alkaline phosphatase were included in the final score. From the training dataset, three groups of increasing risk were defined, and these were associated with hazard ratios (HR) of 2.13 and HR=5.72. Similar results were obtained on the validation dataset. This score provides a better discriminatory ability than BCLC and CLIP in this setting. Unfortunately, absolute performances for these scores remain poor.

Conclusions

The new prognostic score and CLIP+PS are recommended in palliative settings. However, new prognostic variables are necessary.

Keywords: Prognostic factors, Discrimination, Palliative setting, Overall survival

Abbreviations: HCC, hepatocellular carcinoma, BCLC, Barcelona Clinic Liver Cancer, CLIP, Cancer of the Liver Italian Program, WHO, World health organization, PS, performance status, HR, hazard ratio, OS, overall survival, AFP, alpha-foetoprotein, AIC, Akaike information criterion, 95% CI, 95% confidence interval

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0168-8278(10)00705-1

doi:10.1016/j.jhep.2010.06.015

Journal of Hepatology
Volume 54, Issue 1 , Pages 108-114, January 2011